CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


CAPABLE TransitionsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1065 Home Health Agency Care Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D003704 Dementia NIH 0.50

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0000726 Dementia HPO 0.50

There is one clinical trial.

Clinical Trials


1 A Randomized, Unblinded, 60-subject Three-wave Clinical Trial of an Occupational Therapy-led In-home Intervention Designed to Help Older Adults Successfully Transition to Their Homes Following a Skilled Nursing Facility Discharge

This clinical study is designed to test the feasibility of a new intervention, CAPABLE Transitions. CAPABLE Transitions is based on the Community Aging in Place, Advancing Better Living for Elders (CAPABLE) intervention designed by Dr. Sarah Szanton at Johns Hopkins University. Similar to CAPABLE, CAPABLE Transitions consists of an occupational therapy (OT)-led intervention in which the study OT, nurse, and handyman deliver an in-home intervention over 3-4 months. This intervention is designed to help with the transition of care from the skilled nursing facility to home as well as to optimize functioning and home safety. This clinical study plans to recruit a total of 60 older adults with and without dementia admitted to a home health agency following discharge from a skilled nursing facility. Given that this is a feasibility study, it is not designed or powered to test hypotheses.

NCT04460742 Care Transitions Dementia Behavioral: CAPABLE Transitions Behavioral: Home Health Agency Care
MeSH:Dementia
HPO:Dementia

Primary Outcomes

Description: The study will monitor how many older adults are screened and satisfy the eligibility criteria.

Measure: Proportion of participants screened as eligible

Time: Through study completion, an average of 3 years

Description: The study will monitor how many older adults who satisfy the eligibility criteria are enrolled in the study.

Measure: Proportion of screened participants that enroll

Time: Through study completion, an average of 3 years

Description: The study will monitor the proportion of participants that complete the study.

Measure: Proportion of enrolled participants that are retained

Time: 6 months

Description: Participants and study partners will be asked Likert-item response survey questions to assess the perceived benefit and burdensomeness of the intervention.

Measure: Proportion of participants who perceive a benefit from the intervention

Time: 3 months

Description: Participants and study partners will be asked Likert-item response survey questions to assess the perceived benefit and burdensomeness of the intervention.

Measure: Proportion of participants who perceive a benefit from the intervention

Time: 6 months

Description: The study will review audio recordings and study interventionists' documentation to examine fidelity to the intervention and score whether the interventionists completed the central tasks of CAPABLE Transitions. The study will score completion of the critical components as "yes" or "no" and this outcome will be reported as the proportion of critical components of the CAPABLE Transitions intervention that were completed by the occupational therapist and registered nurse.

Measure: Proportion of Critical Tasks Completed

Time: Throughout Study Intervention, an average of 5 months

Description: The study will monitor the proportion of participants who have complete information on home time, quality of life, and health services utilization at 3 months.

Measure: Data Completeness on Clinical Outcomes

Time: 3 months

Description: The study will monitor the proportion of participants who have complete information on home time, quality of life, and health services utilization at 6 months.

Measure: Data Completeness on Clinical Outcomes

Time: 6 months

Secondary Outcomes

Description: Home time is the number of days participants spend alive in non-institutional settings (e.g., nursing homes and hospitals). The study will report the participants' home time at 3 months of follow-up.

Measure: Home Time in Days

Time: 3 months

Description: Home time is the number of days participants spend alive in non-institutional settings (e.g., nursing homes and hospitals). The study will report the participants' home time at 6 months of follow-up.

Measure: Home Time in Days

Time: 6 months

Description: The study will examine quality of life (EQ-5D-5L) among study participants at 3 months of follow-up. Rating: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, each with 1 as lowest score and 5 as highest score: no problems, slight problems, moderate problems, severe problems and extreme problems, where higher scores indicate worse outcome. The EQ VAS question records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine' out of 100. Therefore higher scores may indicate better outcomes.

Measure: Mean change in quality of life using EQ-5D-5L (unabbreviated title)

Time: 3 months

Description: The study will examine quality of life (EQ-5D-5L) among study participants at 6 months of follow-up. Rating: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, each with 1 as lowest score and 5 as highest score: no problems, slight problems, moderate problems, severe problems and extreme problems, where higher scores indicate worse outcome. The EQ VAS question records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine' out of 100. Therefore higher scores may indicate better outcomes.

Measure: Mean change in quality of life using EQ-5D-5L (unabbreviated title)

Time: 6 months

Description: The study will examine the proportion of participants who went to the emergency department, were hospitalized, and were admitted to a skilled nursing facility within 3 months of follow-up. The study also will tabulate the mean number of times they used these services within 3 months of follow-up.

Measure: Health Services Use

Time: 3 Months

Description: The study will examine the proportion of participants who went to the emergency department, were hospitalized, and were admitted to a skilled nursing facility within 6 months of follow-up. The study also will tabulate the mean number of times they used these services within 6 months of follow-up.

Measure: Health Services Use

Time: 6 Months


Related HPO nodes (Using clinical trials)


HP:0000726: Dementia
Genes 290
C9ORF72 HNRNPA2B1 DNAJC13 HTT CHCHD10 HNRNPA1 CLN6 FMR1 PSAP ATXN10 TOMM40 GBA ATXN3 PSEN1 ADH1C GBA2 CHMP2B COX1 TREM2 POLG NOTCH3 PLAU TRNF AARS2 PINK1 VPS13C TBP SYNJ1 MAPT ATXN8OS UCHL1 PSEN1 SNCA FUS TYMP SLC13A5 TRNC PLA2G6 MATR3 EPM2A SNCA C19ORF12 PANK2 SNCA CP PPP2R2B CHMP2B HTT TRNK TRNL1 ND1 ND4 PDGFB RRM2B NR4A2 ERCC8 MPO VPS13A LRRK2 SERPINI1 JPH3 PODXL GIGYF2 ITM2B WDR45 PRNP COX3 TRNQ DNMT1 SPAST SDHB ABCD1 C9ORF72 PRNP GBA PSEN2 NPC2 LRRK2 SQSTM1 GBA TRPM7 CYTB SNCA TRNV MAPT RNF216 HTRA1 COX3 COL4A1 CYP27A1 GRN FTL FMR1 TUBA4A TWNK APP ALDH18A1 MMACHC VPS13C MAPT MBTPS2 TMEM106B SQSTM1 ATP13A2 SPG21 ATN1 APTX GBA HEXA ATP6V0A2 PARK7 ALDH18A1 WDR45 DGUOK HTRA2 ARSA NOTCH2NLC TRNS2 ROGDI MAPT KCTD7 WFS1 TREM2 CISD2 TRNQ VPS35 APOE GBA PRNP PSEN2 HTT TBP HFE CLN3 NHLRC1 TRNS1 UBQLN2 GRN CHCHD10 PNPLA6 TRNH VCP SDHD HTRA1 TYROBP ZFYVE26 HNRNPA2B1 NPC1 TREM2 C9ORF72 SLC2A3 PSEN1 MAPT TYROBP TARDBP CP TREM2 PANK2 DNMT1 RNF216 PINK1 MATR3 ATP6V1A PLA2G6 SNCA SDHAF1 MAPT GRN CSF1R TTR XPR1 COX2 TRNF SDHA VCP SNCAIP SORL1 LRRK2 GRN ATXN2 TARDBP SCARB2 TRNW ATP7B APP GM2A PRDM8 TBK1 PDGFRB PRICKLE1 ATP13A2 IRF6 APOE ROGDI POLG PSEN1 ATXN2 CHMP2B PSEN1 APP PRKAR1B VCP ATP13A2 PRNP ITM2B ATP6 NHLRC1 ATP13A2 TBK1 TRNS2 ASAH1 NOS3 APP A2M EPM2A CSTB DNAJC5 COX1 CTSF CERS1 CHMP2B SQSTM1 WFS1 TRNW TUBB4A APP ATN1 PRNP ND5 C9ORF72 JPH3 SPG21 RAB39B PRKN ND6 MAPT ATXN2 DCTN1 ND5 ABCA7 APP SNCB CUBN PRNP PRNP FBXO7 ERCC4 HLA-DQB1 PSEN1 NDP C9ORF72 TREX1 DCTN1 PRDX1 PPP2R2B VCP TMEM106B SNCA CFAP43 PSEN1 VCP TRNE GBA2 APP NOTCH3 TRNS1 COX2 ATP6V1E1 TREM2 TIMM8A FTL VCP CHMP2B MAPT MECP2 ATP6 MAPT TMEM106B EIF4G1 DNM1L ND6 ADA2 ASAH1 GBE1 TRNL1 CST3 ND1 GLUD2 OPA1 DNAJC6
Protein Mutations 1
V158M
SNP 0